GlassScriptPhysician profile
Karan Saini
NPI 1255802112
$4,320.28
in general payments reported to CMS, 2019-2025
35 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $504 · 2022: $978 · 2023: $184 · 2024: $562 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $954.37 | 2022 | |
| Abbvie INC. | $548.44 | 2021-2025 | |
| Genentech USA, INC. | $275.26 | 2025 | Ocrevus Zunovo |
| Lilly USA, LLC | $271.68 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $257.69 | 2025 | Tysabri, Vumerity, Skyclarys |
| Boston Scientific Corporation | $240.02 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $197.82 | 2023-2024 | Relyvrio |
| Sk Life Science, INC. | $146.81 | 2023-2025 | |
| Stimwave Technologies Incorporated | $129.30 | 2021 | |
| Tg Therapeutics, INC. | $126.92 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $90.48 | 2021-2025 | Austedo Xr, Ajovy |
| Ucb, INC. | $87.79 | 2025 | Zilbrysq, Rystiggo |
| Jazz Pharmaceuticals INC. | $74.45 | 2025 | |
| Novartis Pharmaceuticals Corporation | $70.52 | 2025 | |
| Lundbeck LLC | $70.02 | 2025 | Vyepti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $60.11 | 2025 | Zeposia |
| Tanabe Pharma America, INC. | $57.30 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $56.48 | 2021 | |
| Pfizer INC. | $53.53 | 2025 | |
| Axsome Therapeutics, INC. | $51.26 | 2025 | Sunosi, Symbravo |
| Argenx US, INC. | $50.81 | 2024-2025 | Vyvgart Hytrulo |
| Averitas Pharma INC. | $50.02 | 2025 | Qutenza |
| Genzyme Corporation | $49.11 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $42.78 | 2025 | Lumryz |
| Catalyst Pharmaceuticals, INC. | $41.48 | 2025 | |
| Impel Pharmaceuticals LLC | $39.60 | 2025 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $37.99 | 2025 | Amvuttra |
| Microtransponder, INC. | $34.81 | 2025 | |
| Amgen INC. | $29.09 | 2025 | Uplizna |
| Ani Pharmaceuticals, INC. | $25.35 | 2024 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $23.90 | 2022 | |
| Spr Therapeutics, INC | $23.66 | 2021 | |
| Janssen Biotech, INC. | $19.02 | 2025 | |
| Relievant Medsystems, INC. | $17.84 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.57 | 2024 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.